Acrylamide-encapsulated glucose oxidase inhibits breast cancer cell viability

Rrustemi T., Geyik O. G., Ozkaya A. B., Öztürk T. K., Yüce Z., Kılınç A.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.45, no.6, pp.811-816, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 6
  • Publication Date: 2020
  • Doi Number: 10.1515/tjb-2020-0247
  • Journal Name: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.811-816
  • Keywords: biocompatibility, cancer therapy, glucose oxidase, MCF-7, single enzyme nanoparticle, starving-like therapy, therapeutic enzyme, NANOPARTICLES, ASPARAGINASE
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objectives: Cancer cells modulate metabolic pathways to ensure continuity of energy, macromolecules and redoxhomeostasis. Although these vulnerabilities are often targeted individually, targeting all with an enzyme may prove a novel approach. However, therapeutic enzymes are prone to proteolytic degradation and neutralizing antibodies leading to a reduced half-life and effectiveness. We hypothesized that glucose oxidase (GOX) enzyme that catalyzes oxidation of glucose and production of hydrogen peroxide, may hit all these targets by depleting glucose; crippling anabolic pathways and producing reactive oxygen species (ROS); unbalancing redox homeostasis.